Urgency Incontinence & OAB
Overactive bladder (OAB) is a symptom syndrome of urinary urgency, usually with frequency and nocturia, with or without urgency urinary incontinence (UUI), in the absence of infection or another explanatory pathology.[1] UUI is involuntary urine loss accompanied by, or immediately preceded by, a compelling urge to void. For the reconstructive urologist and urogynecologist, OAB/UUI matters because it is the common storage-phase phenotype that must be separated from outlet obstruction, stress incontinence, pelvic organ prolapse, neurogenic lower urinary tract dysfunction (NLUTD), fistula, and post-surgical bladder dysfunction before any continence operation, outlet procedure, botulinum injection, or neuromodulation plan is chosen.
This page covers the clinical framework and sex-specific diagnostic traps. For procedural selection and comparative treatment options, see the OAB & UUI treatment database.
Definitions and Epidemiology
OAB is defined clinically, not urodynamically. Detrusor overactivity (DO) may be present on filling cystometry, but there are no pathognomonic urodynamic findings that confirm OAB, and the diagnosis begins with symptoms plus exclusion of infection, hematuria, retention, and other causes.[1]
Community prevalence is commonly reported in the 12-17% range and increases with age.[1][2] The clinical phenotype differs by sex:
| Population | Practical pattern |
|---|---|
| Men | OAB symptoms frequently coexist with benign prostatic obstruction (BPO), impaired contractility, nocturnal polyuria, or neurologic disease; storage symptoms should not be presumed to be "just prostate" or "just bladder." |
| Women | OAB/UUI commonly coexists with stress urinary incontinence, genitourinary syndrome of menopause (GSM), recurrent UTI, constipation, and pelvic organ prolapse. |
| Older adults | Frailty, cognition, mobility, diuretics, sleep apnea, edema, constipation, and caregiver access can dominate the symptom burden as much as bladder physiology. |
Pathophysiology
OAB/UUI is the storage-phase consequence of an unstable or hypersensitive bladder system. Mechanisms include:
- Myogenic DO — spontaneous detrusor contractions during filling
- Urothelial / afferent hypersensitivity — urgency at low volumes without large pressure rises
- Outlet-associated remodeling — chronic obstruction produces detrusor hypertrophy, ischemia, fibrosis, impaired compliance, and DO
- Neurogenic disinhibition — suprapontine lesions, Parkinson disease, multiple sclerosis, stroke, spinal disease, and dementia syndromes can produce urgency-predominant LUTS
- Pelvic-floor guarding / dysfunctional voiding — urgency, incomplete emptying, and pelvic pain can reinforce each other
In men older than 50 years, LUTS may be driven by BPH / bladder outlet obstruction, OAB detrusor physiology, or both.[3] This distinction is operative: outlet surgery can improve urgency when obstruction is the driver, but persistent UUI after outlet relief is common when DO or impaired compliance is the dominant substrate.
Diagnosis and Evaluation
Initial workup
The initial evaluation is usually office-based:[1][4][5]
- History — urgency triggers, frequency, nocturia, UUI episodes, pad use, fluid/caffeine/alcohol intake, constipation, UTIs, hematuria, neurologic disease, sleep apnea, edema, pelvic surgery, radiation, medications
- Symptom instruments — OAB-q, ICIQ-OAB, ICIQ-UI-SF, UDI-6; in men add IPSS to separate storage and voiding domains
- Bladder diary — 3-day diary with voided volumes, urgency grade, leakage episodes, fluid intake, nocturnal urine volume, and pad use
- Urinalysis — rule out infection, glycosuria, pyuria, and hematuria
- Post-void residual (PVR) — especially before antimuscarinics, botulinum toxin, or outlet surgery; elevated PVR changes the pathway
- Focused examination — abdominal, neurologic screen, pelvic exam in women, DRE when prostate/outlet disease is relevant
- Cough stress test — when mixed incontinence is possible; urgency leakage and stress leakage frequently coexist
See Assessment Tools & Questionnaires and Urodynamics for instrument and test-selection detail.
When to escalate testing
Do not routinely perform urodynamics, cystoscopy, or imaging for uncomplicated idiopathic OAB at initial presentation.[1] Escalate when the story stops being straightforward:
| Trigger | Why it matters |
|---|---|
| Gross or microscopic hematuria | Malignancy, stone, radiation cystitis, or inflammatory pathology |
| Recurrent UTI / sterile pyuria | Infection, stone, foreign body, mesh erosion, fistula |
| Elevated PVR / weak stream / straining | BOO, detrusor underactivity, neurogenic emptying failure |
| Prior pelvic radiation or major pelvic surgery | Poor compliance, fistula, outlet stenosis, fragile tissue |
| Stage 3-4 prolapse or suspected urethral diverticulum | Anatomic driver of urgency or mixed incontinence |
| Refractory symptoms before botulinum or neuromodulation | Confirms storage vs emptying phenotype and establishes risk |
| Neurologic disease | Reclassify as possible NLUTD; upper-tract risk depends on pressure and emptying |
Sex-Specific Patterns
Men
Male OAB/UUI is often a mixed bladder-prostate problem. Storage symptoms (urgency, frequency, nocturia, UUI) and voiding symptoms (weak stream, hesitancy, intermittency, straining) should be scored separately, because treatment failure is common when one domain is treated while the other is ignored.[3][6]
| Finding | Implication |
|---|---|
| High IPSS storage score, low PVR, good stream | Treat as OAB-predominant LUTS |
| High voiding score, enlarged prostate, elevated PVR | Treat outlet obstruction first or concurrently |
| Urgency after TURP / HoLEP / prostatectomy | Consider persistent DO, infection, bladder-neck contracture, urethral stricture, or radiation cystitis |
| Parkinson disease, stroke, MS, dementia | Avoid assuming BPH; consider neurogenic OAB and cognition-safe therapy |
Antimuscarinics and β3 agonists can be used in men with OAB symptoms, including in selected men with treated or monitored BPH, but PVR and obstructive symptoms determine safety.[1][3][6]
Women
Female OAB/UUI is commonly entangled with stress incontinence, prolapse, menopause-related tissue changes, constipation, recurrent UTI, and pelvic-floor overactivity.[4][5]
| Finding | Implication |
|---|---|
| Positive cough stress test | Treat as mixed incontinence; anti-incontinence surgery may worsen urgency in susceptible patients |
| GSM / atrophic mucosa | Vaginal estrogen can improve local urinary symptoms and reduce recurrent UTI risk; systemic estrogen is not used to treat incontinence |
| Advanced prolapse | Reduction testing and PVR clarify obstruction vs sensory urgency |
| Prior sling or mesh surgery | Consider obstruction, erosion, recurrent SUI, or pain-driven urgency |
Management
Behavioral and pelvic-floor therapy
Behavioral treatment is first-line and remains useful at every step of escalation:[1][7]
- Bladder training — progressive voiding intervals with urge suppression
- Timed voiding — particularly useful for frailty, cognition, or caregiver-dependent toileting
- Fluid timing — avoid excess evening intake; treat nocturnal polyuria rather than blaming all nocturia on OAB
- Caffeine and alcohol reduction — trial elimination when diary shows a temporal relationship
- Constipation treatment — rectal loading worsens urgency and emptying
- Pelvic floor physical therapy — urge-suppression contractions, relaxation of overactive pelvic floor, and coordination training
- Weight loss and exercise — especially when mixed incontinence coexists
See Behavioral Therapy for OAB & UUI for bladder-training protocols, urge-suppression teaching, CBT-informed approaches, weight-loss evidence, and combination behavioral + drug therapy data. In men, a randomized trial found that a stepped strategy beginning with behavioral therapy, then adding drug therapy when needed, is reasonable for OAB symptoms.[7]
Pharmacotherapy
Medication selection should account for cognition, constipation, glaucoma risk, blood pressure, renal function, PVR, polypharmacy, and the need for concurrent outlet therapy.
| Class | Role | Reconstructive / functional cautions |
|---|---|---|
| Antimuscarinics | Reduce urgency, frequency, and UUI episodes | Dry mouth, constipation, blurred vision, retention risk; avoid or minimize in cognitively vulnerable older adults |
| β3 agonists | Similar efficacy with less dry mouth and less cognitive burden | Mirabegron can raise blood pressure; check interactions and baseline hypertension |
| Combination OAB therapy | β3 agonist + antimuscarinic when monotherapy is inadequate | Higher efficacy but more adverse effects and cost; monitor PVR in at-risk patients |
| α-blocker / 5α-reductase inhibitor / tadalafil in men | Treats coexisting BPH/outlet symptoms, not OAB itself | Persistent storage symptoms after outlet therapy may still require OAB-directed treatment |
| Vaginal estrogen in women | Local therapy for GSM-associated urinary symptoms and recurrent UTI risk | Not a primary OAB drug; systemic estrogen is not used for incontinence treatment |
The AUA/SUFU guideline supports offering antimuscarinic medications or β3 agonists to patients with OAB, with shared decision-making around side effects and patient priorities.[1] Contemporary reviews increasingly favor β3 agonists in older or cognitively vulnerable patients when blood pressure and coverage allow.[1][6]
Procedural therapy for refractory OAB/UUI
Patients who fail behavioral and pharmacologic therapy, cannot tolerate medications, or prefer procedural management can move to minimally invasive treatment. These are not "last resort" therapies; they are durable options that require phenotype-specific counseling.[1][6][8]
| Therapy | Best candidate | Key counseling point |
|---|---|---|
| Intradetrusor onabotulinumtoxinA | Refractory OAB-wet, medication intolerance, patient comfortable with cystoscopic repeat treatment | UTI and retention risk; patient must be willing and able to perform CIC if needed |
| Sacral neuromodulation | Refractory urgency-frequency, UUI, non-obstructive retention, mixed storage/emptying phenotypes | Requires test phase, implanted device, MRI-conditional device planning, battery/revision counseling |
| PTNS / TTNS | Patient preferring low-risk office or home neuromodulation | Weekly induction and maintenance; low systemic adverse-effect burden |
Male patients have higher reported intermittent catheterization rates after botulinum toxin than women in some series, especially when baseline emptying is borderline, obstruction coexists, or higher doses are used.[6]
Reconstructive end of the pathway
Augmentation cystoplasty or urinary diversion is rarely needed for idiopathic OAB in the modern botulinum/neuromodulation era, but remains relevant for severe refractory storage failure, poor compliance, high-pressure NLUTD, radiation-damaged bladder, or hostile outlet situations. In those patients, OAB/UUI should be reframed as a safe-storage problem, not merely a symptom-control problem.
Follow-Up and Treatment Failure
Track the same measures used at baseline: diary episodes, urgency grade, nocturia, pad count, PVR, adverse effects, bowel function, and patient-defined bother. If a patient "fails OAB treatment," reassess the diagnosis before escalating:
- Is the leakage actually stress-predominant or fistulous?
- Is nocturia driven by nocturnal polyuria, edema, sleep apnea, or diuretics?
- Is there occult retention from BOO, sling obstruction, antimuscarinic effect, or detrusor underactivity?
- Is recurrent UTI, stone, mesh erosion, radiation cystitis, or bladder pain syndrome driving urgency?
- Is neurologic disease evolving into NLUTD?
See Also
- OAB & UUI treatment database
- Behavioral Therapy for OAB & UUI
- Pelvic Floor Physical Therapy
- Intradetrusor onabotulinumtoxinA
- Sacral Neuromodulation
- Percutaneous Tibial Nerve Stimulation
- Urodynamics
- Mixed Urinary Incontinence
- Neurogenic Lower Urinary Tract Dysfunction
References
1. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985
2. Raju R, Linder BJ. "Evaluation and Treatment of Overactive Bladder in Women." Mayo Clin Proc. 2020;95(2):370-377. doi:10.1016/j.mayocp.2019.11.024
3. Wei JT, Dauw CA, Brodsky CN. "Lower Urinary Tract Symptoms in Men: A Review." JAMA. 2025;334(9):809-821. doi:10.1001/jama.2025.7045
4. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. "Urinary Incontinence in Women: A Review." JAMA. 2017;318(16):1592-1604. doi:10.1001/jama.2017.12137
5. Hu JS, Pierre EF. "Urinary Incontinence in Women: Evaluation and Management." Am Fam Physician. 2019;100(6):339-348. PMID:31524367
6. De Nunzio C, Brucker BM, Bschleipfer T, et al. "Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men." Eur Urol. 2021;79(4):492-504. doi:10.1016/j.eururo.2020.12.032
7. Burgio KL, Kraus SR, Johnson TM, et al. "Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial." JAMA Intern Med. 2020;180(3):411-419. doi:10.1001/jamainternmed.2019.6398
8. Farag F, Sakalis VI, Monagas Arteaga S, et al. "What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel." Eur Urol. 2023;84(3):302-312. doi:10.1016/j.eururo.2023.05.014